What’s Changing?
On June 30, 2025, the U.S. Food and Drug Administration (FDA) issued a safety communication requiring all manufacturers of extended-release (ER) stimulants—including both amphetamine and methylphenidate formulations—used for attention-deficit/hyperactivity disorder (ADHD) to revise their prescribing information (PI). The update mandates inclusion of a “Limitation of Use” section highlighting that children under 6 years old experience higher plasma drug exposure and greater rates of adverse reactions, particularly weight loss, compared to older children taking the same dose U.S. Food and Drug Administration+1.
Why the Update Is Necessary
The FDA’s decision stems from postmarketing requirements under the Pediatric Research Equity Act (PREA), which required pharmacokinetic (PK) and safety evaluations in children aged 4 to 5. Findings revealed:
- Higher systemic exposure in younger children at equivalent doses.
- Clinically significant weight loss, defined as at least a 10% drop in CDC weight percentile, observed in both short- and long-term studies U.S. Food and Drug Administration+1.
- These impacts were consistent across both amphetamine and methylphenidate compounds, indicating a class-wide risk and an unfavorable benefit-risk balance for children under six U.S. Food and Drug Administration+1.
Impacts & Recommendations at a Glance
For Parents and Guardians
- If your child under six is taking an ER stimulant and experiencing weight loss—or other concerning symptoms—contact your pediatrician to reassess whether continued treatment benefits outweigh risks U.S. Food and Drug Administration+1.
- Ask about immediate-release (IR) alternatives, which are sometimes approved for younger children and may reduce appetite suppression and insomnia due to shorter systemic exposure U.S. Food and Drug Administration+1.
- Discuss the role of behavioral therapy, lifestyle adjustments, or non-stimulant medications as safer or complementary treatment options U.S. Food and Drug Administration+1.
For Health Care Providers
- Be aware that ER stimulants are not FDA-approved for children under 6, though off-label use exists. The new PI revisions make this clearer and caution-laden U.S. Food and Drug AdministrationReutersPsychiatric Times.
- Monitor growth and development closely in young patients on these medications; intervene promptly if weight loss or stunted growth emerge U.S. Food and Drug AdministrationPsychiatric Times.
- Consider discontinuing or transitioning to IR stimulants when adverse outcomes occur U.S. Food and Drug AdministrationPsychiatric Times.
- Remain proactive in recommending behavioral ADHD therapies, which can reduce reliance on pharmacological interventions in sensitive age groups U.S. Food and Drug Administration+1.
Bigger Picture: Why This Holds Weight
- Approximately 7 million U.S. children aged 3–17 have been diagnosed with ADHD, highlighting the widespread impact of any regulatory changes in ADHD treatments ReutersU.S. Food and Drug Administration.
- The FDA’s harmonization of PI across the ER stimulant class addresses public health concerns around off-label prescribing in very young children and ensures consistent safety messaging U.S. Food and Drug AdministrationReuters.
- The move reflects evolving regulatory rigor toward precision in pediatric medication safety, aiming to prevent avoidable weight loss, nutritional deficiencies, and long-term growth issues U.S. Food and Drug Administration+1.
Summary Table
| Audience | Key Actions & Insights |
|---|---|
| FDA | Mandated PI revisions for ER stimulants to include Limitation of Use for children <6 years. |
| Manufacturers | Must add or update Limitation of Use sections to ensure unified safety messaging. |
| Providers (Doctors) | Monitor growth; consider IR alternatives; counsel families on safer treatment strategies. |
| Parents/Guardians | Watch for weight/loss-of-appetite; review treatment options; discuss alternatives with HCPs. |
Contextual Insights
- Extended-release stimulants (such as Concerta, Ritalin LA, Adderall XR) offer once-daily dosing benefits but now come with increased caution for off-label pediatric use Wikipedia+1.
- Broadly, methylphenidate is known to cause appetite suppression and mild growth delay—sometimes up to 3 cm over 10 years—adding further weight to the FDA’s updated warning Wikipedia.
Contact us : company@shudarsana.com
Discover more from सुदर्शन
Subscribe to get the latest posts sent to your email.